Poland - Pharmaceutical products

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
03 February 2022
Opportunity publication date
03 January 2022
Category
33600000: Ph
Value of contract
£100k-1m
Your guide to exporting
Report opportunity

Description

A detailed description of the subject matter of the contract, required form, volume/volume, dose, unit of measure, quantity in package, number of packages is specified in the FORM OF ASSORTMENT AND PRICE, constituting Annex No. 1 to the SWZ (SWZ).3 .The series and expiry date on the unit packaging and on the invoice, the expiry date not shorter than 12 months.5, The offered pharmaceutical product must have approval for marketing and use in the Republic of Poland for each required form and dose of the drug separately, according to the Act of 6 September 2001 on Pharmaceutical Law.6. 6. the Contractor shall deliver the subject of the order to the Hospital Pharmacy Warehouse. 7. the time of delivery - according to current needs, each time within maximum 2 working days from the date of placing the order.
Inteferon beta-1aSpecimen Dose Unit of measure Quantity in pack Quantity of injectable solution 44mcg/0.5ml op. Quantity in pack Solution for injection injector 30mcg/0.5ml op. 4 injectors (+4 injection needles + 4 injector shields) 70Quantity expected to be purchased under the right of option 35. Inteferon beta-1b, powder 0.3mg (9.6m IU) of recombinant interferon beta-1b for preparation of 0.25mg/ml solution. Form Dose Unit of measure Quantity in pack Powder and solvent for solution for injection 250mcg/ml pack 15 vials of powder and 15 amp.Dose Unit of measurement Quantity in pack Quantity in pack Quantity in pack Powder for concentrate for solution for infusion 300mg op. 1 vial 80 Quantity to be purchased by right of option 40 Natalizumab Form Dose Unit of measurement Quantity in pack Quantity in pack Concentrate for solution for infusion 300mg op. 1 vial 15ml 30 Quantity to be purchased by right of option 15. Adalimumab Dose Form Unit of measure Quantity in pack Quantity in pack Quantity in pack Solution for injection in ampoule-syringe 40mg/0.8ml op.Dose Unit of measure Quantity in pack Op. 5 mg film-coated tables Op. 56 tables 50 Quantity to be purchased by right of option 25. 1. Description and product parametersHuman normal immunoglobulin for subcutaneous injection, for children or adults; 1l of solution contains 200g of human protein, including at least 98% immunoglobulin, stabilised with glycine, distribution of IgG subclasses: IgG1≥56,9%, IgG2≥ 26,6%, IgG3≥3,4%, IgG4≥ 1,7%; Maximum IgA content is 280 micrograms/ml. Form and Dosage: solution for injection 200mg/ml.3.Capacity/volume: Volumes* Units: 1g/5ml 100 g 2g/10ml 200 g 4g/20ml 400 g Quantity 2 100.4: 1) free lending of pumps for administration of the preparation. The offered pumps must be approved in Poland. The Contractor is obliged to service these devices. 2) supply sets to be delivered with the ordered drug 3) supply sets enabling the transportation of drugs and accessories while maintaining the storage conditions specified in the ChPL - the quantity depending on the Purchaser's needs6. The quantity expected to be purchased under the option right in Appendix 1 to the SWZ. Human Immunoglobulin for subcutaneous administration in children, adolescents (0-18 years) and adults, 200mg/ml. Approximate distribution of IgG subclasses: IgG1 69%, IgG2 26%, IgG3 3%, IgG4 2%. Maximum IgA content is 50 micrograms/ml. Contains approximately 250 mmol/L (range: 210 to 290) L-proline. Manufactured from human plasma. 2.Form and dose Solution for injection, 200mg/ml. Unit of measurement 1g/5ml 50 g 2g/10ml 200 4g/20ml 300 10g/50ml 504.* The Contracting Authority admits the possibility of changing the number of packages in the scope of individual capacities/volumes depending on the demand 5. The Contracting Authority additionally requires for the duration of the contract 1) free lending of pumps for administration of the preparation. The offered pumps must be approved in Poland. The Contractor is obliged to service these devices. 2) administration sets to be delivered with the ordered drug.6 The quantity to be purchased under the option right in Appendix 1 to the SWZ. Product description and parametersHuman normal immunoglobulin for intravenous administration, containing at least 98% IgG. The distribution of the different IgG subclasses (approximate values): IgG 67.8%, IgG2 28.7%, IgG3 2.3%, IgG4 1.2%. The maximum IgA content is 25 micrograms/ml. Manufactured from human plasma. Indicated for replacement therapy and immunomodulation in adults, children and adolescents (0-18 years); for the treatment of Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). Form and dose Solution for infusion, 100mg/ml.3.Capacity/volume; number of units*; unit of measurement; quantity/g; quantity expected to be purchased under the option right is specified in Appendix 1 to the SWZ.4. Glatiramer acetate Form Dose Unit of measure Quantity in pack Quantity of op.solution for injection 40mg/ml op. 12 amp.-injection 160Quantity expected to be purchased under the option right 80. Sofosbuvir + Velpatasvir Form Dose Unit of measure Quantity in pack Quantity of op. coated tablets 400 mg + 100 mg op. 28 tabl. 260Quantity expected to be purchased under the option right 130.

Opportunity closing date
03 February 2022
Value of contract
£100k-1m

About the buyer

Address
Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego ul. Koszarowa 5 Wrocław 51-149 Poland
Contact
enowakowska@szpital.wroc.pl

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?